Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANIX NYSE:JATT NASDAQ:MGNX NASDAQ:ZURA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANIXAnixa Biosciences$3.01-2.9%$3.24$2.07▼$4.20$99.85M0.43108,980 shs57,974 shsJATTJATT Acquisition$1.57+7.5%$1.31$7.80▼$12.38$27.08MN/A41,322 shs411,192 shsMGNXMacroGenics$1.61$1.51$0.99▼$5.10$101.57M1.65702,537 shs256,174 shsZURAZura Bio$1.48-2.6%$1.32$0.97▼$5.07$103.93M-0.06898,305 shs170,876 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANIXAnixa Biosciences-2.90%-1.63%-4.14%+15.33%-0.33%JATTJATT Acquisition0.00%+6.80%+38.94%+27.64%-58.58%MGNXMacroGenics0.00%+3.21%+9.52%+12.59%-52.37%ZURAZura Bio-2.63%+5.71%+23.33%+22.31%-58.07%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANIXAnixa Biosciences3.5063 of 5 stars3.55.00.00.03.33.30.0JATTJATT AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AMGNXMacroGenics4.2626 of 5 stars3.34.00.04.41.82.50.6ZURAZura Bio3.7369 of 5 stars3.65.00.00.03.82.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANIXAnixa Biosciences 3.00Buy$9.00199.00% UpsideJATTJATT Acquisition 0.00N/AN/AN/AMGNXMacroGenics 2.57Moderate Buy$5.40235.40% UpsideZURAZura Bio 3.13Buy$14.33868.47% UpsideCurrent Analyst Ratings BreakdownLatest JATT, ZURA, ANIX, and MGNX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/5/2025ANIXAnixa BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.006/10/2025ANIXAnixa BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.005/29/2025ANIXAnixa BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.005/20/2025MGNXMacroGenicsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$5.00 ➝ $3.005/14/2025MGNXMacroGenicsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$8.00 ➝ $3.005/14/2025MGNXMacroGenicsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$6.00 ➝ $5.005/9/2025ZURAZura BioOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$19.00 ➝ $17.00(Data available from 8/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANIXAnixa Biosciences$210K461.68N/AN/A$0.59 per share5.10JATTJATT AcquisitionN/AN/A$0.06 per share27.08($0.53) per shareN/AMGNXMacroGenics$149.96M0.68N/AN/A$1.85 per share0.87ZURAZura BioN/AN/AN/AN/A$2.27 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANIXAnixa Biosciences-$12.55M-$0.38N/A∞N/AN/A-68.17%-60.38%9/5/2025 (Estimated)JATTJATT Acquisition$6.85MN/A0.00∞N/AN/A-49.58%2.84%N/AMGNXMacroGenics-$66.97M-$0.89N/AN/AN/A-36.23%-59.84%-23.45%N/AZURAZura Bio-$45.39M-$0.70N/AN/AN/AN/A-42.84%-35.22%8/12/2025 (Estimated)Latest JATT, ZURA, ANIX, and MGNX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/5/2025N/AANIXAnixa Biosciences-$0.10N/AN/AN/AN/AN/A8/12/2025Q2 2025ZURAZura Bio-$0.19N/AN/AN/AN/AN/A6/3/2025Q2 2025ANIXAnixa Biosciences-$0.10-$0.09+$0.01-$0.09N/AN/A5/13/2025Q1 2025MGNXMacroGenics-$0.61-$0.65-$0.04-$0.65$9.59 million$13.19 million5/8/2025Q1 2025ZURAZura Bio-$0.17-$0.19-$0.02-$0.19N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANIXAnixa BiosciencesN/AN/AN/AN/AN/AJATTJATT AcquisitionN/AN/AN/AN/AN/AMGNXMacroGenicsN/AN/AN/AN/AN/AZURAZura BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANIXAnixa BiosciencesN/A8.898.89JATTJATT AcquisitionN/A0.150.15MGNXMacroGenicsN/A3.283.11ZURAZura BioN/A8.148.14Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANIXAnixa Biosciences29.13%JATTJATT Acquisition47.97%MGNXMacroGenics96.89%ZURAZura Bio61.14%Insider OwnershipCompanyInsider OwnershipANIXAnixa Biosciences25.30%JATTJATT Acquisition20.00%MGNXMacroGenics13.00%ZURAZura Bio14.23%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANIXAnixa Biosciences532.21 million24.06 millionOptionableJATTJATT Acquisition317.25 million13.80 millionNot OptionableMGNXMacroGenics43063.09 million54.89 millionOptionableZURAZura Bio368.38 million58.65 millionOptionableJATT, ZURA, ANIX, and MGNX HeadlinesRecent News About These CompaniesZura Bio Limited (NASDAQ:ZURA) Receives Average Recommendation of "Buy" from BrokeragesAugust 7 at 3:54 AM | marketbeat.comZura Bio (ZURA) Projected to Post Quarterly Earnings on TuesdayAugust 6 at 10:28 AM | marketbeat.comZura Bio (NASDAQ:ZURA) Shares Up 7.5% - What's Next?August 6 at 4:26 AM | marketbeat.comRobert Lisicki on Living Up to Zura Bio’s Heroic NamesakeJuly 31, 2025 | pharmexec.comP3 Penny Stocks With Market Caps Over $70M Worth WatchingJuly 18, 2025 | finance.yahoo.comZura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 18, 2025 | finance.yahoo.comZura Bio Limited (NASDAQ:ZURA) Given Consensus Recommendation of "Buy" by AnalystsJuly 13, 2025 | marketbeat.comZura Bio (NASDAQ:ZURA) Trading 12.5% Higher - Here's What HappenedJuly 10, 2025 | marketbeat.comZura Bio Announces Chief Financial Officer TransitionJuly 1, 2025 | businesswire.comZura Bio shareholders approve board nominees and auditorMay 24, 2025 | investing.comZura Bio commences Phase II trial of tibulizumab for hidradenitis suppurativaMay 21, 2025 | msn.comZura Bio Launches Global Phase 2 TibuSHIELD Study to Evaluate Tibulizumab in Adults with Hidradenitis SuppurativaMay 20, 2025 | businesswire.comZura Bio Reports First Quarter 2025 Financial Results and Recent Corporate UpdatesMay 9, 2025 | standard-journal.comSAfter losing 56% in the past year, Zura Bio Limited (NASDAQ:ZURA) institutional owners must be relieved by the recent gainApril 24, 2025 | finance.yahoo.comZura Bio price target lowered to $3 from $5 at H.C. WainwrightApril 4, 2025 | markets.businessinsider.comZura Bio (ZURA) Gets a Buy from GuggenheimMarch 31, 2025 | markets.businessinsider.comHopeful Week For Insiders Who Bought US$1.01m Of Zura Bio StockMarch 26, 2025 | finance.yahoo.comZura Bio Limited: 2024 Financial Results and Strategic ProgressMarch 25, 2025 | tipranks.comZura Bio Reports Full Year 2024 Financial Results and Recent Corporate UpdatesMarch 25, 2025 | businesswire.comZura Bio to Present at the Leerink Partners Global Healthcare ConferenceFebruary 24, 2025 | businesswire.comZURA stock touches 52-week low at $1.44 amid market shiftsFebruary 11, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Short Squeeze Candidates With Big Catalysts on the HorizonBy Dan Schmidt | July 25, 2025View 3 Short Squeeze Candidates With Big Catalysts on the HorizonWhy the American Eagle Stock Rally Isn't Just Speculation By Gabriel Osorio-Mazilli | July 28, 2025View Why the American Eagle Stock Rally Isn't Just Speculation America Wants Drone Dominance: Are These Stocks Ready to Soar?By Chris Markoch | July 20, 2025View America Wants Drone Dominance: Are These Stocks Ready to Soar?Super Micro Computer Sees Unusual Volume—Catalyst Ahead?By Gabriel Osorio-Mazilli | July 25, 2025View Super Micro Computer Sees Unusual Volume—Catalyst Ahead?Does Broadcom Have a VMware Problem? Goldman Eyes Upside in NTNXBy Leo Miller | August 6, 2025View Does Broadcom Have a VMware Problem? Goldman Eyes Upside in NTNXJATT, ZURA, ANIX, and MGNX Company DescriptionsAnixa Biosciences NASDAQ:ANIX$3.01 -0.09 (-2.90%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$3.13 +0.12 (+4.12%) As of 08/7/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.JATT Acquisition NYSE:JATT$1.57 +0.11 (+7.53%) As of 08/5/2025JATT Acquisition Corp does not have significant operations. It intends to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company intends to focus on businesses primarily operating in the life sciences sector. JATT Acquisition Corp was incorporated in 2021 and is based in Grand Cayman, the Cayman Islands.MacroGenics NASDAQ:MGNX$1.61 0.00 (0.00%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$1.61 0.00 (0.00%) As of 08/7/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.Zura Bio NASDAQ:ZURA$1.48 -0.04 (-2.63%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$1.46 -0.02 (-1.35%) As of 08/7/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Constellation Energy’s Earnings Beat Signals a New Era AppLovin’s Q2 Miss Spooks Market, But Wall Street Doubles Down Realty Income Rallies Post-Earnings Miss—Here’s What Drove It Don't Mix the Signal for Noise in Super Micro Computer's Earnings Microsoft Stock Gains as Analysts Boost Price Targets Joby Deal Gives Blade New Direction, But Stock Lacks Lift Uber Technologies Is Driving Cash Flow: Ride It Higher for Life How DigitalOcean's Focus Is Fueling Explosive Growth Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
